Home
/
Inhibikase Therapeutics, Inc.
/
Financials
/
Quarterly
Inhibikase Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Inhibikase Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 14, 2025
Q2
2025
Jun 30, 2025
$0
Aug 14, 2025
Q1
2025
Mar 31, 2025
$0
May 14, 2025
Q3
2025
Sep 30, 2024
$0
Nov 14, 2025
Q2
2025
Jun 30, 2024
$0
Aug 14, 2025
Q1
2025
Mar 31, 2024
$0
May 14, 2025
Q3
2023
Sep 30, 2023
$79.6K
Nov 14, 2023
Q2
2023
Jun 30, 2023
$116.4K
Aug 14, 2023
Q1
2024
Mar 31, 2023
$64.5K
May 15, 2024
Q3
2023
Sep 30, 2022
$7.3K
Nov 14, 2023
Q2
2023
Jun 30, 2022
$6.6K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$46.0K
May 15, 2023
Q3
2022
Sep 30, 2021
$328.5K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$1.36M
Aug 12, 2022
Q1
2022
Mar 31, 2021
$1.41M
May 16, 2022
Q3
2021
Sep 30, 2020
$37.7K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$219.6K
Aug 16, 2021
Q1
2021
Mar 31, 2020
$270.8K
May 17, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($11.93M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($9.92M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($9.92M)
Nov 14, 2025
Q1
2025
Mar 31, 2025
($13.68M)
May 14, 2025
Q2
2025
Mar 31, 2025
($13.68M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($13.68M)
Nov 14, 2025
Q3
2025
Sep 30, 2024
($5.78M)
Nov 14, 2025
Q3
2025
Jun 30, 2024
($4.96M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($4.96M)
Aug 14, 2025
Q2
2025
Mar 31, 2024
($4.65M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($4.65M)
Nov 14, 2025
Q1
2025
Mar 31, 2024
($4.65M)
May 14, 2025
Q3
2024
Sep 30, 2023
($4.60M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($5.78M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($5.78M)
Nov 14, 2024
Q3
2024
Mar 31, 2023
($4.48M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($4.48M)
May 15, 2024
Q2
2024
Mar 31, 2023
($4.48M)
Aug 14, 2024
Q3
2023
Sep 30, 2022
($4.49M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($4.64M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.77M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($10.83M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($14.60M)
May 14, 2025
Q3
2025
Sep 30, 2024
($5.83M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($5.05M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($4.78M)
May 14, 2025
Q3
2023
Sep 30, 2023
($4.77M)
Nov 14, 2023
Q2
2023
Jun 30, 2023
($6.20M)
Aug 14, 2023
Q1
2024
Mar 31, 2023
($4.71M)
May 15, 2024
Q3
2023
Sep 30, 2022
($4.51M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($4.64M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($4.64M)
May 15, 2023
Q3
2022
Sep 30, 2021
($4.47M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($2.63M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($2.63M)
May 16, 2022
Q3
2021
Sep 30, 2020
($663.7K)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($413.9K)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($540.0K)
May 17, 2021